Bernini F, Paoletti R
Istituto di Scienze Farmacologiche, Università di Milano.
Eur J Epidemiol. 1992 May;8 Suppl 1:104-6. doi: 10.1007/BF00145360.
Calcium antagonists (CA) exert an anti-atherosclerotic effect in cholesterol-fed rabbits through reduction of cholesterol accumulation in the arterial wall. Further studies in our Institute indicate that verapamil-like compounds and diltiazem stimulate receptor-mediated LDL uptake by human fibroblasts in culture, while nifedipine-like compounds and flunarizine are inactive. Verapamil and diltiazem stimulated LDL-receptor activity also in cells from a heterozygous FH patient, while they were inactive in a receptor defective homozygous FH patient. A basic group needs to be present on the CA molecule to modulate the LDL receptor expression. Preliminary data in our laboratory suggest that some CA can achieve concentrations in the aortic wall likely to exert effects on LDL receptors. This stimulatory activity may improve lipid metabolism in the arterial wall.
钙拮抗剂(CA)通过减少胆固醇在动脉壁中的积聚,对喂食胆固醇的兔子发挥抗动脉粥样硬化作用。我们研究所的进一步研究表明,维拉帕米类化合物和地尔硫䓬可刺激培养的人成纤维细胞通过受体介导摄取低密度脂蛋白(LDL),而硝苯地平类化合物和氟桂利嗪则无此活性。维拉帕米和地尔硫䓬在杂合子家族性高胆固醇血症(FH)患者的细胞中也能刺激LDL受体活性,但在受体缺陷的纯合子FH患者细胞中则无活性。CA分子上需要存在一个碱性基团来调节LDL受体的表达。我们实验室的初步数据表明,一些CA在主动脉壁中能够达到可能对LDL受体产生作用的浓度。这种刺激活性可能会改善动脉壁中的脂质代谢。